Oncolytic therapy is a new cancer treatment that employs genetically modified viruses to kill cancer cells while preserving normal tissue. The session "Oncolytic Therapy" discusses the mechanisms, clinical applications, and most recent advances in this innovative therapeutic strategy.
Oncolytic viruses infect cancer cells, replicate inside of them, and induce cell lysis. This does not only directly kill cancer cells but also activates the immune system to be able to recognize and destroy residual tumor cells, affording a twofold anti-cancer effect. Different cancer-specific viral platforms are being developed by researchers, such as adenoviruses, herpes simplex viruses, and vaccinia viruses.
This session also discusses combination strategies, in which oncolytic therapy is combined with immunotherapy, chemotherapy, or radiation to maximize treatment benefits. Clinical trials are assessing safety, efficacy, and ideal delivery, pointing to the promise of oncolytic therapy in increasing survival in patients with refractory or advanced cancers.
Participants will learn about the biology of oncolytic viruses, recent research, and new therapies in this arena. This session highlights the revolutionary potential of oncolytic therapy as a new, targeted, and immune-activating modality, bringing new hope for cancer prevention and treatment.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
